Floatz logo

Nivolumab

Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8

Fred Hutchinson Cancer Centermonoclonal_antibodyPhase 2Active
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
48/ 100
Competitive Position
89/ 100

Competitive context

4 Active assets in the Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8 cohort.

Asset / SponsorPhaseRating
Ipilimumab
National Cancer Institute (NCI)
Phase 1/2CCC
PREDNISONE TABLETS
National Cancer Institute (NCI)
Phase 1/2CCC
Rapamycin
National Cancer Institute (NCI)
Phase 1/2CC
TACROLIMUS
National Cancer Institute (NCI)
Phase 1CC

Same molecule, other indications

Nivolumab is also rated in:

Recurrent Non-Hodgkin LymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
renal carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
metastatic melanomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →